Sibeprenlimab Halves uPCR in IgA Nephropathy Trial ...Middle East

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent safety outcomes, interim phase 3 data shows. Medscape Medical News

Hence then, the article about sibeprenlimab halves upcr in iga nephropathy trial was published today ( Friday 06/06/2025 - 09:58 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sibeprenlimab Halves uPCR in IgA Nephropathy Trial )

Also on site :

• Blessing Muzarabani ditches PSL team, joins KKR for IPL 2026
• Force majeure: What is it and why have some Gulf countries invoked it?
• Tetragon Financial Group Limited Announcement of Tender Offer to Purchase $50,000,000 of Tetragon Non-Voting Shares